CHAI vs Clinical Judgment: A New Frontier in NMIBC Personalization

Drs. Vignesh T. Packiam and Nitin Yerram explore the latest advances in NMIBC, including combination immunotherapy with BCG, emerging data in papillary disease, and the development of AI-driven biomarkers like CHAI to guide personalized treatment decisions.

In this segment, they break down the development of the CHAI biomarker, an AI-powered pathology tool trained on over 1,000 patient samples from 10 institutions, designed to predict response to BCG in high-grade NMIBC.

Advertisement

Latest News

Advertisement
Advertisement
Editorial Advisory Board

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.

This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

Conference Coverage

Live meeting highlights

Scott Tagawa, MD, MS, FACPRLT | July 18, 2025
Drs. Tagawa and Marulanda Corzo discuss the use of single time-point SPECT/CT dosimetry for 177Lu-PSMA targeted RLT.
Nadine Mallak, MDProstate Cancer Diagnostics | July 15, 2025
Dr. Nadine Mallak talks about 18F-fluciclovine to detect disease in BCR of prostate cancer when the standard of care fails.
Brittany Miles, MDProstate Cancer Diagnostics | July 15, 2025
Dr. Miles highlights the dilemma of managing PC with BCR after prostatectomy but no visible disease on standard imaging.
Koichiro Kimura, MD, PhDRLT | July 8, 2025
Dr. Kimura shares insights on PSMA PET/CT metrics and their potential role in guiding treatment decisions for mCRPC.